PE20190968A1 - Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih - Google Patents

Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih

Info

Publication number
PE20190968A1
PE20190968A1 PE2019001082A PE2019001082A PE20190968A1 PE 20190968 A1 PE20190968 A1 PE 20190968A1 PE 2019001082 A PE2019001082 A PE 2019001082A PE 2019001082 A PE2019001082 A PE 2019001082A PE 20190968 A1 PE20190968 A1 PE 20190968A1
Authority
PE
Peru
Prior art keywords
compounds
inhibitors
useful
hiv
tetraciclic
Prior art date
Application number
PE2019001082A
Other languages
English (en)
Inventor
Thomas Dean Graham
Tao Yu
Yonglian Zhang
John A Mccauley
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60703169&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20190968(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of PE20190968A1 publication Critical patent/PE20190968A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/16—Peri-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV

Abstract

Referido a compuestos heterociclos tetraciclicos de formula (I), en donde: ---- es un doble enlace opcional; el anillo A, incluyendo los atomos de C y N con los que se condensa, es un heterocicloalquilo monociclico o biciclico de 5 a 8 miembros; X es heteroarilo monociclico de 5 o 6 miembros y -N(R4)C(O)-; R1 es fenilo que se sustituye opcionalmente; R2 es H, alquilo C1-C6, entre otros; R3 es H, -O-(alquilo C1-C6), entre otros; R7 es H o alquiloC1-C6. Dichos compuestos son inhibidores de la integrasa del VIH. Tambien se refiere a una composicion farmaceutica que comprenden dicho heterociclo tetraciclico siendo utiles para tratar o prevenir la infeccion por VIH en un sujeto
PE2019001082A 2016-12-02 2017-11-30 Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih PE20190968A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662429470P 2016-12-02 2016-12-02

Publications (1)

Publication Number Publication Date
PE20190968A1 true PE20190968A1 (es) 2019-07-08

Family

ID=60703169

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019001082A PE20190968A1 (es) 2016-12-02 2017-11-30 Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih

Country Status (26)

Country Link
US (2) US10479801B2 (es)
EP (1) EP3548493B1 (es)
JP (1) JP6778325B2 (es)
KR (1) KR102345924B1 (es)
CN (1) CN110214142B (es)
AR (1) AR110298A1 (es)
AU (1) AU2017367610B2 (es)
BR (1) BR112019010924B1 (es)
CA (1) CA3045311C (es)
CL (1) CL2019001495A1 (es)
CO (1) CO2019005534A2 (es)
CR (1) CR20190257A (es)
DO (1) DOP2019000140A (es)
EA (1) EA039853B1 (es)
EC (1) ECSP19041050A (es)
ES (1) ES2837806T3 (es)
GE (1) GEP20227353B (es)
IL (1) IL266908A (es)
JO (1) JOP20190130A1 (es)
MX (1) MX2019006447A (es)
PE (1) PE20190968A1 (es)
PH (1) PH12019501198A1 (es)
TN (1) TN2019000170A1 (es)
TW (1) TWI756312B (es)
UA (1) UA125472C2 (es)
WO (1) WO2018102485A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
JP7328962B2 (ja) 2018-05-31 2023-08-17 塩野義製薬株式会社 多環性カルバモイルピリドン誘導体
SG11202011386QA (en) 2018-05-31 2020-12-30 Shionogi & Co Polycyclic pyridone derivative
WO2019236396A1 (en) 2018-06-05 2019-12-12 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
SG11202107145SA (en) 2019-01-25 2021-08-30 Univ Brown Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders
US11084832B2 (en) 2019-03-22 2021-08-10 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
CR20220418A (es) * 2020-02-24 2022-10-10 Gilead Sciences Inc Compuestos tetracíclicos para el tratamiento de infecciones por vih
HUE064467T2 (hu) 2021-01-19 2024-03-28 Gilead Sciences Inc Szubsztituált piridotriazin-származékok és alkalmazásuk
AU2022223241A1 (en) 2021-02-16 2023-08-24 Merck Sharp & Dohme Llc Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100491349C (zh) 2001-08-10 2009-05-27 盐野义制药株式会社 抗病毒药
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
PL212914B1 (pl) 2001-10-26 2012-12-31 Angeletti P Ist Richerche Bio N-podstawione hydroksypirymidynonokarboksyamidy jako inhibitory integrazy HIV
ES2291642T3 (es) 2002-01-17 2008-03-01 MERCK & CO., INC. Hidroxinaftiridinoncarboxamidas utiles como inhibidores de la integrasa de vih.
CA2481449A1 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Method and compositions for identifying anti-hiv therapeutic compounds
WO2004058757A1 (en) 2002-12-27 2004-07-15 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors
US7135467B2 (en) 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
AR046938A1 (es) 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
EP1725554A1 (en) * 2004-03-09 2006-11-29 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
EP1973906A1 (en) 2004-12-23 2008-10-01 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
AU2006228278C1 (en) 2005-03-31 2011-06-23 Msd Italia S.R.L. HIV integrase inhibitors
ES2437268T3 (es) * 2005-04-28 2014-01-09 Viiv Healthcare Company Derivado de carbamoilpiridona policíclico que tiene actividad inhibidora de la integrasa del VIH
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
JP2006342115A (ja) 2005-06-10 2006-12-21 Shionogi & Co Ltd Ｈｉｖインテグラーゼ阻害活性を有する多環性化合物
US7494984B2 (en) 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
CA2626956A1 (en) 2005-10-27 2007-05-03 Shionogi & Co., Ltd. Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity
US7897592B2 (en) 2005-11-15 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7902182B2 (en) 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
EP2465858B1 (en) 2008-07-25 2013-12-25 VIIV Healthcare Company Process for preparing a pyrido[1,2-a]pyrrolo[1',2':3,4]imidazo[1,2-d]pyrazine-8-carboxamide derivative
JP5572168B2 (ja) 2008-12-11 2014-08-13 ビーブ・ヘルスケア・カンパニー カルバモイルピリドンｈｉｖインテグラーゼ阻害剤の製造方法および中間体
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011011483A1 (en) 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
SG183484A1 (en) 2010-02-26 2012-09-27 Japan Tobacco Inc 1,3,4,8-tetrahydro-2h-pyrido[1,2-a]pyrazine derivative and use of same as hiv integrase inhibitor
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
RU2567385C2 (ru) 2010-04-02 2015-11-10 ЯНССЕН Ар ЭНД Ди АЙРЛЭНД Макроциклические ингибиторы интегразы
US9216995B2 (en) 2010-04-12 2015-12-22 Shionogi & Co., Ltd. Pyridone derivative having integrase inhibitory activity
BR112013002461A2 (pt) 2010-08-05 2016-05-24 Shionogi & Co método para produzir um composto, e, cristal de um composto
WO2012095388A2 (en) 2011-01-10 2012-07-19 Universität Zürich Compounds for treatment of feline leukemia in felidae
US20140213553A1 (en) 2011-05-03 2014-07-31 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
US9206197B2 (en) 2011-09-14 2015-12-08 Mapi Pharma Ltd. Amorphous form of dolutegravir
EP2774928B1 (en) 2011-10-12 2017-08-30 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
EP2931730B1 (en) 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
US9216996B2 (en) 2012-12-21 2015-12-22 Gilead Sciences, Inc. Substituted 2,3,4,5,7,9,13,13a-octahydropyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazepines and methods for treating viral infections
JP6320039B2 (ja) 2012-12-27 2018-05-09 日本たばこ産業株式会社 置換されたスピロピリド［１，２−ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての医薬用途
DK2997033T3 (da) * 2013-05-17 2018-01-29 Merck Sharp & Dohme Kondenserede tricykliske heterocykliske forbindelser som hiv- integrasehæmmere
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JP6411491B2 (ja) 2013-07-12 2018-10-24 ギリアード サイエンシス インコーポレーテッド 多環式カルバモイルピリドン化合物およびｈｉｖ感染症を処置するためのその使用
NO2865735T3 (es) 2013-07-12 2018-07-21
WO2015039348A1 (en) 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MD4794B1 (ro) 2013-09-27 2022-02-28 Merck Sharp & Dohme Corp Derivaţi de chinolizină substituiţi utili ca inhibitori de integrază HIV
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
EP3196201B1 (en) * 2014-08-22 2021-04-28 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
WO2016090545A1 (en) 2014-12-09 2016-06-16 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrate inhibitors
WO2016187788A1 (en) * 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)

Also Published As

Publication number Publication date
CA3045311C (en) 2021-05-04
ECSP19041050A (es) 2019-06-30
CN110214142A (zh) 2019-09-06
AU2017367610A1 (en) 2019-06-13
EP3548493A1 (en) 2019-10-09
BR112019010924A2 (pt) 2019-10-01
JP2019536791A (ja) 2019-12-19
PH12019501198A1 (en) 2020-02-10
DOP2019000140A (es) 2019-07-31
CR20190257A (es) 2019-07-02
US10479801B2 (en) 2019-11-19
KR102345924B1 (ko) 2022-01-04
AR110298A1 (es) 2019-03-13
UA125472C2 (uk) 2022-03-23
ES2837806T3 (es) 2021-07-01
TWI756312B (zh) 2022-03-01
JOP20190130A1 (ar) 2019-06-02
CN110214142B (zh) 2022-04-01
CA3045311A1 (en) 2018-06-07
EA039853B1 (ru) 2022-03-21
AU2017367610B2 (en) 2020-03-19
GEP20227353B (en) 2022-02-25
EA201991349A1 (ru) 2019-12-30
MX2019006447A (es) 2019-09-16
IL266908A (en) 2019-07-31
WO2018102485A1 (en) 2018-06-07
US20190315769A1 (en) 2019-10-17
TW201827437A (zh) 2018-08-01
US20180155365A1 (en) 2018-06-07
US10829499B2 (en) 2020-11-10
CL2019001495A1 (es) 2019-08-16
TN2019000170A1 (en) 2020-10-05
BR112019010924B1 (pt) 2020-11-24
JP6778325B2 (ja) 2020-10-28
KR20190086755A (ko) 2019-07-23
CO2019005534A2 (es) 2019-06-11
EP3548493B1 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
PE20190968A1 (es) Compuestos de heterociclo tetraciclicos utiles como inhibidores de la integrasa del vih
AR114164A1 (es) Piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
CL2019000271A1 (es) Inhibidores de polimerasa hcv. (divisional solicitud 201600493)
PE20191260A1 (es) Compuestos inhibidores del vih
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
CL2016000698A1 (es) Derivados de quinolizina sustituidos útiles como inhibidores de integrasa del vih
CU20170089A7 (es) Derivados de quinazolina utilizados para tratar el vih
ECSP17002135A (es) Compuestos antiproliferativos y métodos de uso de los mismos
CL2019000512A1 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
BR112016016844A2 (pt) Compostos heterocíclicos
PE20120659A1 (es) Inhibidores de la replicacion del virus de la inmunodeficiencia humana
PE20130010A1 (es) Derivado de 1,3,4,8-tetrahidro-2h-pirido[1,2-a]pirazina como inhibidor de la integrasa del vih
MX2018008095A (es) Compuestos heterociclicos triciclicos condensados como inhibidores de integrasa del vih.
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
PE20142081A1 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodo de uso de los mismos
NI201200146A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
AR104878A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR125457A2 (es) Compuestos inhibidores dobles de magl y faah y composición farmacéutica
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia